Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

Peskar, BM; Sawka, N; Ehrlich, K; Peskar, BA.
Role of cyclooxygenase-1 and -2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection.
J Pharmacol Exp Ther. 2003; 305(3):1233-1238 Doi: 10.1124/jpet.103.049650 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz
Peskar Bernhard
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Oral administration of the nonselective cyclooxygenase (COX) inhibitor indomethacin (20 mg/kg), the COX-1 inhibitor 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560) (20 mg/kg), or the COX-2 inhibitor rofecoxib (1-20 mg/kg) antagonized the gastroprotective effects of 16,16-dimethyl-prostaglandin (PG) E2 (75 ng/kg p.o.) and 20% ethanol in rats. The effects of the COX inhibitors were reversed by the activator of ATP-sensitive potassium (KATP) channels cromakalim (0.3-0.5 mg/kg p.o.). The protective effects of 16,16-dimethyl-PGE2 and 20% ethanol were counteracted by the phospholipase C inhibitor 1-(6-((17 beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U-73122), but not its inactive analog 1-(6-((17 beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-2,5-pyrrolidine-dione (U-73343) (1 mg/kg each i.v.). Likewise, the protein kinase C inhibitors chelerythrine (0.7 mg/kg i.v.) and staurosporine (3 microg/kg i.v.) inhibited gastroprotection. Effects of these enzyme inhibitors were not reversed by cromakalim. Submaximally effective doses of SC-560 (0.2 mg/kg p.o.) and rofecoxib (0.02 mg/kg p.o.) were additive and abolished the protection induced by 20% ethanol. The findings show that inhibition of COX-1 or COX-2 antagonizes not only adaptive gastroprotection by 20% ethanol but also the protective effect of exogenous PG in a cromakalimsensitive manner. Endogenous PG obviously add to the protective activity of exogenous PG. Gastroprotection by PG involves phospholipase C, protein kinase C, and KATP channels. Activation of KATP channels does not exert protection when the activity of phospholipase C or protein kinase C is suppressed.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Cromakalim - pharmacology
Cyclooxygenase 1 - pharmacology
Cyclooxygenase 2 - pharmacology
Cyclooxygenase 2 Inhibitors - pharmacology
Cyclooxygenase Inhibitors - pharmacology
Digestive Physiology - pharmacology
Dinoprost - analogs and derivatives
Enzyme Inhibitors - pharmacology
Estrenes - pharmacology
Ethanol - pharmacology
Isoenzymes - drug effects
Male - drug effects
Membrane Proteins - drug effects
Phospholipase C - drug effects
Prostaglandin-Endoperoxide Synthases - drug effects
Prostaglandins - physiology
Protein Kinase C - drug effects
Pyrrolidinones - pharmacology
Rats - pharmacology
Rats, Wistar - pharmacology

© Med Uni GrazImprint